Follicular dendritic cell sarcoma of the stomach: case report and review of the literature

D. Shaw MD,* R. Cuison MD,† and H. Ito MD*

ABSTRACT

Follicular dendritic cell sarcoma (FDCS) is a rare entity, often presenting a diagnostic challenge for both the pathologist and the clinician. It accounts for only 0.4% of soft-tissue sarcomas, and its underlying causes are largely unknown. Most of these tumors occur in lymph nodes, and extranodal involvement is uncommon. In the gastrointestinal tract, FDCS is extremely rare. Here, we report a case of primary FDCS originating in the stomach. Upon review of the literature, we identified only 2 additional cases of FDCS presenting as a primary stomach tumor. Given the rarity of this tumor in gastrointestinal sites and the lack of consensus on treatment, evaluation of this entity must continue.

KEY WORDS

Follicular dendritic cell sarcoma, stomach malignancy

1. INTRODUCTION

Follicular dendritic cells are a component of the humoral immune response, cooperating with dendritic cells and Langerhans cells. They form a nonlymphoid accessory component to the humoral response by providing antigen presentation and B-cell response maturation. In contrast to bone marrow hematopoiesis-derived dendritic cells, follicular dendritic cells are of mesenchymal origin.

Follicular dendritic cell sarcoma (FDCS) is a rare entity, accounting for only 0.4% of soft-tissue sarcoma. Follicular dendritic cell sarcoma often arises in lymph nodes. It is found most commonly in the cervical, mediastinal, and axillary areas. Primary gastrointestinal cases of FDCS are extremely rare, having been described in few case reports to date. Reported extranodal sites include colon, appendix, small bowel, and liver. Here, we report a patient with FDCS arising in the stomach. To our knowledge, ours is the third case of gastric FDCS reported in the literature. Given the relative paucity of information related to intervention in gastric FDCS, an improved description of the disease process and treatment modalities is essential.

2. CASE DESCRIPTION

Our patient, a 60-year-old woman, originally presented with crampy epigastric pain. Her associated symptoms included nausea and vomiting. Her physical exam demonstrated only a tender and irreducible mass near the umbilicus. Given her incarcerated hernia, she was taken to the operating room and underwent resection of entrapped omentum and ileum. She underwent umbilical hernia repair without complications.

Histologic examination of the hernia content demonstrated a 2×1.4×1.2 cm focus of FDCS within necrotic fat. Computed tomography imaging demonstrated a suspicious mass at the pylorus, with no additional evidence of metastasis on positron-emission tomography. Preoperative esophagogastroduodenoscopy demonstrated only mild gastritis near the pylorus, with submucosal bulging. Biopsies confirmed the lesion to be FDCS. The patient was taken for an exploratory laparotomy, and she underwent distal gastrectomy, with a palpable tumor discovered at the pylorus. The patient underwent a Billroth II reconstruction. She elected not to receive adjuvant therapy. Unfortunately, she developed liver recurrence and died at 8 months after presentation.

FIGURE 1 Abdominal computed tomography images showed a mass (arrow) in the pylorus of the stomach. (A) Coronal section. (B) Axial section.
Histologic examination of the resected surgical specimen showed sheets and ill-defined fascicles and whorls of oval-to-spindle cells with ill-defined cytoplasmic borders and vesicular—at times pleomorphic—nuclei, with prominent nucleoli. Interspersed among the tumour cells were numerous small non-neoplastic lymphocytes. Mitotic figures were easily seen (Ki-67 immunoproliferative index of approximately 40%). Immunoperoxidase staining showed tumour cells to be reactive with CD21 and vimentin. There was no reactivity with antibodies to CD45, CD117, CD43, CD34, CD1a, CD3, CD20, PAX5, Ki-1, CD68, Alk1, Leu-M1, myeloperoxidase, CAM 5.2, SI00, calretinin, melanoma cocktail, muscle actin, desmin, synaptophysin, and chromogranin.

3. LITERATURE REVIEW

A search of the literature at PubMed, using the term “follicular dendritic cell tumor” combined with “extranodal,” “stomach,” and “gastrointestinal,” identified relevant articles for review. Articles were limited to English. References of the collected articles were also used to identify other publications of relevance. Primary nodal tumours were disregarded.

4. DISCUSSION

Follicular dendritic cell sarcoma is an uncommon tumour, and extranodal disease accounts for only one third of FDGS cases\(^1\). Most of the extranodal disease shows a predilection for head and neck locations\(^1\). Examining all extranodal FDGS disease together, background characteristics have been described. The age of patients with extranodal FDGS is variable, with the mean falling in the 5th decade of life, and the disease is slightly more common in women (1.2:1)\(^1\). The causes of FDGS are largely unknown. Associations with Castleman disease\(^1\)\(^2\) and Epstein–Barr viral infection\(^1\)\(^3\) have been reported. The Epstein–Barr virus is suspected to carry a viral oncogene—latent membrane protein 1—that might encourage transformation. In addition, relationships have been found with autoimmune diseases such as paraneoplastic pemphigus\(^1\)\(^4\) and myasthenia gravis\(^1\)\(^5\). It is suggested that FDGS encourages aberrant immune system activation, given that patients often demonstrate immature T cells.

Gastrointestinal FDGS tumours often present as slow-growing and painless masses\(^6\)\(^6\). However, their location is variable, and the abdominal pain can be nonspecific. For the abdominal component of this disease, common imaging findings include a well-defined mass with regional lymphadenopathy and homogenous enhancement with internal necrosis and often with internal calcifications\(^7\)\(^7\). The primary differential diagnosis includes gastrointestinal stromal tumour and primary gastrointestinal lymphomas. The inflammatory pseudotumour-like FDGS variant must also be considered. The latter entity shows greater prevalence in liver and spleen and presents primarily in women. Histology shows atypical spindle cells scattered by prominent lymphoplasmacytic infiltrate, with expression of CD21, CD23, CD35, and D2-40\(^8\)\(^8\).

One third of FDGS tumours are initially misdiagnosed\(^9\). The most common reason for misdiagnosis is a failure to consider FDGS at the initial pathology evaluation. A routine immunohistochemistry panel will often not test the required markers, making the diagnosis difficult. In addition, FDGS can express markers typical for T-cell lymphoma, which can delay a correct diagnosis\(^6\). Tissue diagnosis is essential for FDGS; biopsy samples classically demonstrate fusiform ovoid cells in whirling pattern [Figure 2(A)]. Multiple markers, including CD21, CD35, and CD23, can be used for confirmation\(^1\)\(^9\) [Figure 2(B)]. Other markers that can stain positive include CD23, vimentin, CD68, SI00 protein, fascin, and Ki-M4p, although they lack specificity\(^2\)\(^0\). One study noted that, FDGS is positive for CD21 83% of the time, CD23 90% of the time, and CD35 44% of the time, with wide variability compared with other studies\(^2\)\(^1\)\(^2\)\(^2\).

**FIGURE 2** Tumour histology. (A) Section demonstrates fusiform cells in whirling patterns (hematoxylin and eosin stain; 20× original magnification). (B) Positive staining for CD21 is a characteristic feature of follicular dendritic cell sarcoma (20× magnification).
This tumour is treated as an intermediate-grade soft-tissue sarcoma. Surgical resection is preferred, and there is no consensus on optimal chemotherapy and adjuvant therapy\textsuperscript{22}. The CHOP (cyclophosphamide–hydroxydaunorubicin–vincristine–prednisolone) chemotherapy regimen is perhaps the most widely used, producing some degree of response as defined by increased tumour necrosis and decreased uptake on positron-emission tomography\textsuperscript{23}. Other centres are using chemotherapy regimens consistent with sarcoma treatment (doxorubicin, ifosfamide, gemcitabine, and vinorelbine)\textsuperscript{24}. An alternative to doxorubicin, polyethylene glycol liposomal doxorubicin, has also been used, with a favourable response and a favourable side effect and pharmacokinetic profile in FDGS of the neck\textsuperscript{25}. Response to chemotherapy has been modest at best.

Overall, the prognosis for FDGS is concerning, with one study reporting recurrence, metastasis, and mortality rates to be 35%, 35%, and 18% respectively in its population\textsuperscript{12}. However, those data must be interpreted cautiously, because follow-up in the latter dataset ranged from 2 months to 9 years. Other series suggested that the 2- and 5-year disease-free survival rates were only 57% and 32%\textsuperscript{22}. Compared with patients having nodal FDGS, those with extranodal FDGS have a worse prognosis. Factors portending poorly for patients have included a tumour diameter greater than 6 cm, intra-abdominal involvement, coagulative necrosis, high mitotic count (>5 of 10 high-power fields), and significant cellular atypia\textsuperscript{12}. Spontaneous regression has been reported, perhaps suggesting an incomplete understanding of the pathophysiology\textsuperscript{26}.

A number of factors could be responsible for the worse prognosis in intraabdominal, extranodal FDGS. In one study that demonstrated worse prognosis with intraabdominal FDGS, the authors also demonstrated a trend toward higher recurrence\textsuperscript{12}. Interestingly, hepatic lesions recurred far less frequently (3 of 12 patients) than did extrahepatic lesions (15 of 25 patients). In addition, the intraabdominal tumours were larger on average (9.5 cm) than those at other sites (5.3 cm). It is possible that the delay in diagnosis, with the resulting increase in lesion size, is more responsible than a true difference in FDGS biology for the increased recurrence. Other studies have not demonstrated worse prognosis with intraabdominal involvement\textsuperscript{27}. It is plausible that other factors, such as size or delay in diagnosis, could be confounding factors in the outcome studies. Our review noted that abdominal pain was the most common manifestation of intraabdominal FDGS, but that such pain was present in only 78 of 236 previously described cases. Of those cases, 11 were diagnosed incidentally. Table 1 summarizes our review of demographics, treatment, and prognosis in gastrointestinal FDGS.

Given the criticality of the prognosis as described earlier, there is a need for the creation of better prognostic systems to guide optimal treatment for FDGS. Li and colleagues\textsuperscript{22} reported a scheme that stratifies tumours into low-, medium-, and high-risk groups based on size and tumour grade. Their model demonstrated good stratification of mortality rates (0%, 4%, and 45% for patients with low-, medium-, and high-risk tumours respectively) over a 120-month surveillance period. This prognostic system is probably useful for selecting patients who should receive aggressive adjuvant therapy after surgical resection. To validate the prognostic system for this rare disease, compilation of the data for each case from multiple institutions is critical.

5. CONCLUSIONS

The complex entity FDGS and its gastrointestinal variant is poorly described in the literature. Patients with gastrointestinal FDGS often present late, with vague

<table>
<thead>
<tr>
<th>Reference</th>
<th>Pt age (years)</th>
<th>Cancer location</th>
<th>Treatment modality</th>
<th>Follow-up (months)</th>
<th>Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Han et al., 2000\textsuperscript{10}</td>
<td>45</td>
<td>Stomach</td>
<td>Surgery</td>
<td>10</td>
<td>None</td>
</tr>
<tr>
<td>Geerts et al., 2004\textsuperscript{9}</td>
<td>40</td>
<td>Stomach</td>
<td>Surgery</td>
<td>1.15</td>
<td>None</td>
</tr>
<tr>
<td>Khalid et al., 2005\textsuperscript{24}</td>
<td>19</td>
<td>Liver</td>
<td>Chemo</td>
<td>24</td>
<td>None</td>
</tr>
<tr>
<td>Shia et al., 2006\textsuperscript{3}</td>
<td>30</td>
<td>Rectum</td>
<td>Surgery</td>
<td>15</td>
<td>Disease recurrence</td>
</tr>
<tr>
<td>Soriano et al., 2007\textsuperscript{21}</td>
<td>25</td>
<td>Pancreas</td>
<td>Surgery and radiation therapy</td>
<td>14</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>Granados et al., 2008\textsuperscript{7}</td>
<td>57</td>
<td>Liver</td>
<td>Surgery</td>
<td>24</td>
<td>None</td>
</tr>
<tr>
<td>De Pas et al., 2008\textsuperscript{28}</td>
<td>53</td>
<td>Liver</td>
<td>Surgery</td>
<td>22</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>Kang et al., 2010\textsuperscript{17}</td>
<td>52</td>
<td>Descending colon</td>
<td>Surgery</td>
<td>8</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>Shen et al., 2009\textsuperscript{5}</td>
<td>43</td>
<td>Appendix</td>
<td>Surgery</td>
<td>8</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>Yamada et al., 2009\textsuperscript{6}</td>
<td>82</td>
<td>Small intestine</td>
<td>Surgery and chemotherapy</td>
<td>12</td>
<td>None</td>
</tr>
<tr>
<td>Li et al., 2010\textsuperscript{22}</td>
<td>45</td>
<td>Liver</td>
<td>Surgery</td>
<td>27</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td></td>
<td>36</td>
<td>Mesentery</td>
<td>Surgery</td>
<td>36s</td>
<td>Distant metastasis</td>
</tr>
</tbody>
</table>

Pt = patient.
symptoms. Pathology confirmation is challenging, thus leading to a further delay in diagnosis. Surgical resection remains essential for definitive treatment, especially in gastric disease; and as yet, no consensus on adjuvant therapy has been developed. Further research into the pathogenesis and therapy of FDCS is needed to improve outcomes in this rare disease.

6. CONFLICT OF INTEREST DISCLOSURES

The authors have no financial conflicts of interest to declare.

7. REFERENCES


Correspondence to: Hiromichi Ito, Department of Surgery, College of Human Medicine, Michigan State University, 1200 E. Michigan Avenue, Suite 655, Lansing, Michigan 48912 U.S.A.

E-mail: Hiromichi.ito@hc.msu.edu

* Department of Surgery, College of Human Medicine, Michigan State University, Lansing, MI, U.S.A.
† Department of Laboratories, Sparrow Hospital, Lansing, MI, U.S.A.